Historically, the biopharma industry has not prioritized reduction of manufacturing costs – instead the main concerns have been quality, safety, and time to market. However, the industry is facing cost pressures from increased competition from both biosimilars and multiple treatments for the same disease. Additionally, as patient populations grow and new drugs are introduced, drug pricing increasingly becomes a societal issue. Hence, the issue of manufacturing costs has started to become a serious challenge for the industry. At Pall Biotech, we recognize that continuous bioprocessing offers the greatest potential for cost savings in biomanufacturing. Accordingly, we have developed a portfolio of continuous processing technologies and supporting consumables. We continue to expand this portfolio through in-house development programs. Our aim is to develop a complete suite of products applicable not just to commercial-scale drug manufacture, but also to early stage drug development. In all cases, the focus is fi rmly on maintaining or improving biopharmaceutical quality and lowering costs.